Evidence map›Paper›PMID 38835038›Full record

ArticleBreast cancer research : BCR2024

Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.

Marisa M Faraldo, Mathilde Romagnoli, Loane Wallon, Pierre Dubus, Marie-Ange Deugnier, Silvia Fre

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marisa M FaraldoLaboratory of Genetics and Developmental Biology, Institut Curie, INSERM U934, CNRS UMR3215, PSL Research University, 75248, Paris, France. maria-luisa.martin-faraldo@curie.fr.
Mathilde RomagnoliLaboratory of Cell Biology and Cancer, CNRS UMR144, Institut Curie, PSL Research University, 75248, Paris, France.
Loane WallonLaboratory of Genetics and Developmental Biology, Institut Curie, INSERM U934, CNRS UMR3215, PSL Research University, 75248, Paris, France.
Pierre DubusDepartment of Histology and Pathology, Centre Hospitalier Universitaire de Bordeaux, 33000, Bordeaux, France.
Marie-Ange DeugnierLaboratory of Cell Biology and Cancer, CNRS UMR144, Institut Curie, PSL Research University, 75248, Paris, France.
Silvia FreLaboratory of Genetics and Developmental Biology, Institut Curie, INSERM U934, CNRS UMR3215, PSL Research University, 75248, Paris, France. Silvia.fre@curie.fr.

Funding

ARC - Research association against cancer ARCPGA2021120004232_4874Fondation pour la Recherche Médicale EQU201903007821Fondation Schlumberger pour l'éducation et la recherche FSER20200211117Labex CelTisPhybio ANR-10-LABX-0038Labex DEEP ANR 11-LBX-0044Ligue Nationale Contre le Cancer RS16/75-70
6 · The paper itself

Abstract

backgroundThe aberrant amplification of mammary luminal progenitors is at the origin of basal-like breast cancers associated with BRCA1 mutations. Integrins mediate cell-matrix adhesion and transmit mechanical and chemical signals that drive epithelial stem cell functions and regulate tumor progression, metastatic reactivation, and resistance to targeted therapies. Consistently, we have recently shown that laminin-binding integrins are essential for the expansion and differentiation of mammary luminal progenitors in physiological conditions. As over-expression of the laminin-binding α6 integrin (Itgα6) is associated with poor prognosis and reduced survival in breast cancer, we here investigate the role of Itgα6 in mammary tumorigenesis.

methodsWe used Blg-Cre; Brca1

resultsWe show that Itga6 deletion favors activation of p16 cell cycle inhibitor in the preneoplastic tissue. Subsequently, the amplification of luminal progenitors, the cell of origin of Brca1-deficient tumors, is restrained in Itgα6-deficient gland. In addition, the partial EMT program operating in Brca1/p53-deficient epithelium is attenuated in the absence of Itgα6. As a consequence of these events, mammary tumor formation is delayed in Itgα6-deficient mice. After tumor formation, the lack of Itgα6 does not affect tumor growth but rather alters their differentiation, resulting in reduced expression of basal cell markers.

conclusionsOur data indicate that Itgα6 has a pro-tumorigenic role in Blg-Cre; Brca1

Indexed as

BRCA1 ProteinBreast NeoplasmsIntegrin alpha6Tumor Suppressor Protein p53AnimalsCell ProliferationCell Transformation, NeoplasticFemaleGene DeletionHumansMiceNeoplastic Stem CellsStem CellsBRCA1 ProteinBrca1 protein, mouseIntegrin alpha6Trp53 protein, mouseTumor Suppressor Protein p53Brca1/p53-deficient tumorsLaminin-binding integrinsLuminal progenitors

Identifiers

PMID38835038
PMCPMC11151721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.